Blueprint Medicines Corp is a biopharmaceutical company... Show more
The Moving Average Convergence Divergence (MACD) for BPMC turned positive on June 02, 2025. Looking at past instances where BPMC's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 29, 2025. You may want to consider a long position or call options on BPMC as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The 10-day moving average for BPMC crossed bullishly above the 50-day moving average on May 02, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The 50-day moving average for BPMC moved above the 200-day moving average on June 04, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BPMC advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 212 cases where BPMC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BPMC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BPMC broke above its upper Bollinger Band on June 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BPMC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (24.155) is normal, around the industry mean (16.658). P/E Ratio (0.000) is within average values for comparable stocks, (59.923). BPMC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.234). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (14.451) is also within normal values, averaging (258.761).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
a developer of cancer therapies that harness the growing understanding of the molecular blueprint of cancer
Industry Biotechnology
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
PAVE | 42.63 | 0.42 | +1.00% |
Global X US Infrastructure Dev ETF | |||
PSFM | 29.67 | 0.15 | +0.52% |
Pacer Swan SOS Flex (April) ETF | |||
EMXF | 41.61 | 0.13 | +0.31% |
iShares ESG Advanced MSCI EM ETF | |||
SMMU | 49.93 | -0.05 | -0.10% |
PIMCO Short Term Municipal Bond Actv ETF | |||
SCD | 16.57 | -0.26 | -1.54% |
LMP Capital and Income Fund |
A.I.dvisor indicates that over the last year, BPMC has been loosely correlated with VERA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if BPMC jumps, then VERA could also see price increases.
Ticker / NAME | Correlation To BPMC | 1D Price Change % | ||
---|---|---|---|---|
BPMC | 100% | -0.04% | ||
VERA - BPMC | 47% Loosely correlated | -25.89% | ||
LYRA - BPMC | 44% Loosely correlated | -4.15% | ||
ORIC - BPMC | 42% Loosely correlated | +1.75% | ||
ROIV - BPMC | 42% Loosely correlated | +0.27% | ||
INSM - BPMC | 42% Loosely correlated | +1.21% | ||
More |